Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001026004 | SCV001188303 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-07-25 | criteria provided, single submitter | clinical testing | The c.7071G>A (p.M2357I) alteration is located in exon 48 (coding exon 47) of the ATM gene. This alteration results from a G to A substitution at nucleotide position 7071, causing the methionine (M) at amino acid position 2357 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001832363 | SCV002313683 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-06-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 826819). This missense change has been observed in individual(s) with breast cancer (PMID: 33646313). This variant is present in population databases (rs753951063, gnomAD 0.003%). This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 2357 of the ATM protein (p.Met2357Ile). |
Baylor Genetics | RCV003461412 | SCV004213948 | uncertain significance | Familial cancer of breast | 2021-12-09 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001832363 | SCV002080119 | uncertain significance | Ataxia-telangiectasia syndrome | 2021-04-23 | no assertion criteria provided | clinical testing |